Article Sidebar

Submitted
6 August 2020
Accepted
6 August 2020
Published
30 June 2020
Download
PDF
Statistic
Read Counter : 723 Download : 1801

Main Article Content

Abstract

This review presents key publications from the research field of new biomarker of sepsis and other relevant journals during 2009-2015. The results of these experimental studies and clinical trials are discussed in the context of biomarker for sepsis and the accuracy of presepsin for optimising antibiotic therapy. The discussion highlights and summarises articles on three main topics: diagnostic and prognostic biomarkers, presepsin as new biomarkers, and outcome studies. According to the review, presepsin is specific biomarker for bacterial infections compare with CRP and PCT. It may be useful to evaluate the empirical antibiotic outcome in sepsis condition.

Keywords

Septic condition antibiotic therapy biomarker presepsin bacterial infection CRP PCT

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite
Puspitasari, A. C., & Mawari, A. (2020). Review Article: Presepsin: New Biomaker to Evaluate Empirical Antibiotic Therapy Outcome in Septic Condition. Folia Medica Indonesiana, 56(2), 148–153. https://doi.org/10.20473/fmi.v56i2.21236
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Behnes M, Bertsch T, Lepiorz D, et al (2014). Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care 18, 507
  2. Billeter M, Turina B, Seifert L, Mica R, et al (2009). Early serum procalcitonin, interleukin-6, and 24-hour lactate clearance: useful indicators of septic infections in severely traumatized patients. World Journal of Surgery 33, 558-566
  3. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, et al (2010). Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375, 463-474
  4. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, Periat P, Bucher HC, Christ-Crain M (2008). Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 168
  5. Camacho CH, Juan L (2014). Review article: biomarkers for sepsis. Hindawi Publishing Corporation, BioMed Research International
  6. Charles P-E, Gibot S (2014). Predicting outcome in patients with sepsis: new biomarker for old expectation, Critical Care 18
  7. Charles PE, Tinel C, Barbar S, Aho S, Prin S, Doise JM, Olsson NO, Blettery B, Quenot JP (2009). Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 13, R38
  8. Chenevier-Gobeaux C, Borderie D, Weiss N, et al (22015). Presepsin (sCD14-ST), an innate immune response marker in sepsis. Clin Chim Acta 450, 97-103
  9. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B (2006). Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 84-93
  10. Dupuy A-M, Philippart F, Péan Y, Lasocki S, Charles P-E, Chalumeau M, Claessens Y-E, et al (2013). Role of biomarkers in the management of antibiotic therapy : an expert panel review : I - currently available biomarkers for clinical use in acute infection. Annals of Intensive Care 3, 22
  11. Endo S, Suzuki Y, Takahashi G, et al (2014). Presepsin as a powerful monitoring tool for theprognosis and treatment of sepsis: a multicenter prospective study. J Infect Chemother 20, 30-4
  12. Gilbert DN (2010). Use of plasma procalcitonin levels as an adjunct to clinical microbiology,” Journal of Clinical Microbiology, vol. 48, no. 7, pp. 2325-2329, 2010.
  13. Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, Schroeder S (2009). Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 13, R83
  14. Hofer N, Zacharias E, Muller W, Resch B (2012). An update on the use of C-reactive protein in early-onset neonatal sepsis : current insights and new tasks. Neonatology 102, 25-36
  15. Hou Y-S, Wang H, Chen H, Wu L-F, Lu L-F, He Y (2015). Presepsin assay for early diagnosis of systemic inflammatory response syndrome in patients with nephrolithiasis. Biomed Research International 2015
  16. Julian-Jimenez A, Candel-Gonzalez FJ, Gonzalez DCJ (2014). Usefulness of inflammation and infection biomarkers in the Emergency Department. Enferm Infecc Microbiol Clin 32, 177-90
  17. Katzung BG, Masters SB, Trevor AJ (2012). Basic & clinical pharmacology. 12th Ed. New York, McGrawHill Companies
  18. Kibe S, Adams K, Barlow G (2011). Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 66, ii33-40
  19. Kweon OJ, Choi JH, Park SK, et al (2014). Usefulness of presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. J Crit Care 29, 965-70
  20. Limper M, de Kruif MD, Duits AJ, Brandjes DPM, van Gorp ECM (2010). The diagnostic role of Procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. Journal of Infection 60, 409-416
  21. Liu B, Chen YX, Yin Q, Zhao YZ, Li CS (2013). Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Critical Care 17, R244
  22. Manian FA (2012). Use of procalcitonin to guide duration of antimicrobial therapy in intensive care units: proceed with caution. Clinical Infectious Diseases 54, 578-579
  23. Masson S, Caironi P, Fanizza C, et al (2015). Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med 41, 12-20
  24. Masson S, Caironi P, Spanuth E, et al (2014). Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the albumin Italian outcome sepsis trial. Crit Care 18, R6
  25. Medzhitov R, Janeway Jr C (2000). Innate immunity. N Engl J Med 343, 338-44
  26. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J (2008). Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177, 498-505
  27. Okamura Y, Yokoi H (2011). Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta 412, 2157-61
  28. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Medicine 9
  29. Shirakawa K, Naitou K, Hirose J, Takahashi T, Furusako S (2011). Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. Clin Chem Lab Med 49, 937-9
  30. Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S (2011). Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 17, 764-9
  31. Stocker M, Fontana M, El Helou S, Wegscheider K, Berger TM (2010). Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology 97, 165-174
  32. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M (2009). Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomized study. Eur Respir J 34, 1364-1375
  33. Tang BM, Eslick GD, Craig JC, McLean AS (2007). Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and metaanalysis. Lancet Infect Dis 7, 210-7
  34. Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, et al (2013). Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Critical Care 17, R168
  35. Vincent J, Beumier M (2013). Diagnostic and prognostic markers in sepsis. Expert Review of Anti-Infective Therapy 11, 265-275
  36. Wu C-C, et al (2017). Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systemic review and meta-analysis. Annals of Intensive Care 7
  37. Yu H, Qi Z, Hang C, Fang Y, Shao R, Li C (2017). Evaluating the value of dynamic procalcitonin and presepsin measurement for patient with severe sepsis. American Journal of Emergency Medicine 35
  38. Zheng Z, Jiang L, Ye L, Gao Y, Tang L, Zhang M (2015). The accuracy of presepsin for the diagnosis of sepsis from SIRS: a systemic review and meta-analysis. Annals of Intensive Care 48